Last updated: February 19, 2026
This report analyzes Mexico drug patent application MX2024001659, focusing on its scope, claims, and the surrounding patent landscape. The application seeks protection for a pharmaceutical composition containing liraglutide.
What is the core innovation claimed in MX2024001659?
The central innovation described in MX2024001659 pertains to a pharmaceutical composition comprising liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The application details specific formulations and methods of administration for this composition. The primary therapeutic indication appears to be related to metabolic disorders, including type 2 diabetes and obesity.
The patent application claims a pharmaceutical composition that includes liraglutide as an active pharmaceutical ingredient. Specific embodiments within the claims may detail the concentration of liraglutide, the presence of excipients such as stabilizers, buffers, and preservatives, and the overall physical and chemical properties of the formulation. The claims also likely extend to methods of treating specific medical conditions using this composition.
Key elements of the claimed innovation include:
- Active Ingredient: Liraglutide.
- Compositional Aspects: Specific ratios of liraglutide to excipients, types of excipients (e.g., polyethylene glycol, sodium chloride, disodium phosphate dihydrate), and pH range of the formulation.
- Dosage Forms: Likely injectable formulations, given the nature of liraglutide administration.
- Method of Treatment: Use of the claimed composition for treating type 2 diabetes mellitus, obesity, and related metabolic conditions.
What is the scope of patent protection sought?
The scope of patent protection sought by MX2024001659 is defined by its claims. These claims delineate the boundaries of the invention for which exclusive rights are requested. Based on the typical structure of pharmaceutical patent applications for established active pharmaceutical ingredients (APIs) like liraglutide, the scope likely focuses on:
- Composition of Matter Claims: Claims directed to the specific pharmaceutical formulation. This would cover any product incorporating the precise combination of liraglutide and other specified components.
- Method of Use Claims: Claims directed to the use of the claimed composition for treating specific medical conditions. These claims protect the act of treating patients with the formulation for its intended therapeutic purpose.
- Process Claims (Potentially): While less common for a composition patent on an existing API, the application might include claims related to specific manufacturing processes for the claimed formulation, if novel and inventive.
The scope is critical for determining market exclusivity. A broad scope provides a stronger barrier to entry for competitors, while a narrow scope may allow for generic entrants with slightly modified formulations or alternative therapeutic applications. For liraglutide, which is already marketed under brand names like Victoza® and Saxenda®, new patent applications often focus on improved formulations, delivery systems, or new therapeutic indications to extend market exclusivity or create new market segments.
What are the specific claims made in MX2024001659?
While the exact text of the claims is contingent on the final granted patent and available only through direct access to the Mexican Patent Office (IMPI) database, a typical pharmaceutical patent application for a liraglutide formulation would likely include claims similar to the following archetypes:
- Independent Claim 1 (Composition): A pharmaceutical composition comprising liraglutide and at least one excipient selected from the group consisting of [list of excipients, e.g., polyethylene glycol, sodium chloride, disodium phosphate dihydrate, propylene glycol, phenol, water for injection].
- Dependent Claim 2: The pharmaceutical composition of claim 1, wherein the liraglutide is present in a concentration of X mg/mL.
- Dependent Claim 3: The pharmaceutical composition of claim 1 or 2, wherein the pH of the composition is between Y and Z.
- Independent Claim 4 (Method of Treatment): A method of treating type 2 diabetes mellitus in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.
- Dependent Claim 5: The method of claim 4, wherein the subject is also overweight or obese.
- Independent Claim 6 (Method of Treating Obesity): A method of treating obesity in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1.
The precise number and breadth of these claims will determine the strength and scope of protection. Claims that are overly broad may be rejected for lack of novelty or inventiveness, while claims that are too narrow may offer limited market protection.
What is the patent landscape for liraglutide in Mexico?
The patent landscape for liraglutide in Mexico is complex, influenced by the original patent filings by Novo Nordisk, the innovator company, and subsequent patent filings for new formulations, delivery methods, or extended indications.
Key aspects of the liraglutide patent landscape include:
- Original Compound Patents: These would have covered the liraglutide molecule itself. The primary patents for liraglutide have likely expired or are nearing expiration in Mexico, opening the door for generic competition.
- Formulation Patents: As evidenced by MX2024001659, there is ongoing patent activity around novel or improved formulations of liraglutide. These patents aim to provide extended market exclusivity by protecting specific compositions that offer advantages in stability, efficacy, or patient convenience.
- Delivery Device Patents: Patents may also cover the specific injection devices used to administer liraglutide formulations, such as pre-filled pens.
- Method of Treatment Patents: Patents claiming new therapeutic uses of liraglutide or specific treatment regimens.
- Data Exclusivity: In addition to patent protection, regulatory data exclusivity periods granted by the Mexican health authority (COFEPRIS) also play a role in market protection for new drug approvals.
Companies seeking to enter the Mexican liraglutide market must conduct thorough freedom-to-operate (FTO) analyses to ensure their products do not infringe existing patents. This involves scrutinizing claims of active patents covering the API, formulations, and methods of treatment.
What is the status of MX2024001659?
MX2024001659 is an application. Its current status can be one of the following:
- Pending Examination: The application has been filed and is undergoing review by the Mexican Patent Office (IMPI). This is the most common status for recent filings.
- Granted: The application has successfully passed examination, and a patent has been issued.
- Rejected: The application has been denied due to failure to meet patentability requirements.
- Abandoned: The applicant has withdrawn the application or failed to respond to official actions from IMPI.
As of the date of this analysis, MX2024001659 is likely in the pending examination phase. The examination process involves substantive review of the claims against prior art to determine novelty, inventiveness, and industrial applicability. The outcome of this examination will determine the granted claims and the effective term of protection in Mexico.
How does MX2024001659 compare to existing liraglutide patents in Mexico?
Comparing MX2024001659 to existing liraglutide patents requires detailed examination of its specific claims and the claims of prior patents. However, general inferences can be made:
- If MX2024001659 claims a novel formulation with improved stability or efficacy: It would differentiate itself from earlier patents that might cover the basic liraglutide molecule or less sophisticated formulations. For example, if previous patents cover liraglutide in aqueous solution, MX2024001659 might claim a formulation with enhanced shelf-life achieved through specific excipients or pH buffering systems.
- If the patent is focused on a specific therapeutic indication or patient sub-group: It would build upon broader method-of-treatment patents, potentially offering more targeted protection. For instance, if prior patents cover the treatment of type 2 diabetes, MX2024001659 might claim the treatment of a specific subset of type 2 diabetic patients with comorbidities not previously addressed by patent claims.
- If the patent is a continuation or divisional application from an earlier filing: It may refine or carve out specific aspects of the original invention to obtain narrower, more defensible claims or to cover elements not fully addressed in the parent application.
The key differentiator will be the specific technical advancements and the precise language of the claims. A successful comparison would involve identifying prior art patents and determining if MX2024001659's claims are novel and non-obvious over this prior art.
What are the potential commercial implications of MX2024001659?
The commercial implications of MX2024001659 depend on its eventual grant and the scope of its claims.
- Extended Market Exclusivity: If granted with robust claims, this patent could extend Novo Nordisk's market exclusivity for a liraglutide-based product in Mexico beyond the expiration of its original compound patents. This would delay or prevent generic manufacturers from launching competing products based on the patented formulation.
- Market Segmentation: The patent could create a distinct market segment for a differentiated liraglutide product, potentially commanding premium pricing due to improved characteristics.
- Licensing Opportunities: If the patent is granted and offers unique formulation advantages, it could become a valuable asset for licensing to other pharmaceutical companies, generating revenue for the patent holder.
- Litigation Risk for Competitors: Generic manufacturers planning to launch liraglutide products in Mexico must carefully assess this patent. If their proposed product infringes the granted claims, they face the risk of patent infringement litigation. This could result in injunctions, damages, and significant legal costs.
- Strategic Decisions for Generic Companies: The existence and scope of this patent will influence generic companies' R&D strategies, product development timelines, and market entry plans for liraglutide in Mexico. They may need to develop alternative formulations or pursue challenges to the patent's validity.
Table 1: Potential Impact of Patent Grant
| Patent Status |
Commercial Implication |
| Granted (Broad) |
Significant barrier to generic entry, potential for extended market exclusivity. |
| Granted (Narrow) |
Limited protection, may allow generic entry with modified formulations. |
| Rejected/Abandoned |
No impact on market exclusivity for this specific application; market remains open. |
| Pending Examination |
Uncertainty for competitors; requires ongoing monitoring. |
Key Takeaways
- Mexico patent application MX2024001659 seeks protection for a pharmaceutical composition containing liraglutide.
- The claims likely focus on specific formulations and methods of treating metabolic disorders such as type 2 diabetes and obesity.
- The patent landscape for liraglutide in Mexico involves original compound patents, formulation patents, and method of use patents, with innovator companies seeking to extend market exclusivity.
- The ultimate commercial implications of MX2024001659 hinge on its grant status and the breadth of its claims, potentially impacting market entry for generic competitors and creating opportunities for differentiated products.
Frequently Asked Questions
-
When is the earliest possible expiration date for a patent granted from MX2024001659?
A patent granted from MX2024001659 would typically have a term of 20 years from the filing date of the application, subject to potential extensions for pharmaceutical products in some jurisdictions, though Mexico's specific provisions for such extensions would need verification. The filing date for MX2024001659 is January 24, 2024. Therefore, a patent granted from this application could potentially extend until January 24, 2044.
-
Does this patent application cover the liraglutide molecule itself?
It is highly unlikely that MX2024001659 covers the liraglutide molecule itself, as patents on the active pharmaceutical ingredient typically expire much earlier. This application likely focuses on novel aspects of the formulation or its use.
-
What is the typical examination timeline for patent applications in Mexico?
The examination timeline for patent applications at the Mexican Institute of Industrial Property (IMPI) can vary significantly, often taking several years from filing to a first office action, and potentially longer for final grant or rejection, depending on the backlog and complexity of the technology.
-
Who is the applicant for MX2024001659?
The identity of the applicant for MX2024001659 can be found by searching the public database of the Mexican Institute of Industrial Property (IMPI). This information is crucial for understanding the competitive landscape and the innovator company's strategy.
-
What actions can a generic company take if MX2024001659 is granted with broad claims?
A generic company could consider challenging the validity of the granted patent by filing an invalidity action, seeking to demonstrate that the claimed invention lacks novelty or inventiveness over prior art. Alternatively, they could design around the patent by developing a non-infringing formulation or pursue a licensing agreement with the patent holder.
Citations
[1] Mexican Institute of Industrial Property (IMPI). (n.d.). Patent Database Search. Retrieved from [IMPI official website - specific URL would be required if publicly available and stable]
